TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 52, 2014, Pages 18691-18696

  Otomo, Ryo ^a,b   Otsubo, Chihiro ^c   Matsushima Hibiya, Yuko ^a   Miyazaki, Makoto ^a,d   Tashiro, Fumio ^b   Ichikawa, Hitoshi ^a   Kohno, Takashi ^a   Ochiya, Takahiro ^a   Yokota, Jun ^a   Nakagama, Hitoshi ^a   Taya, Yoichi ^e   Enari, Masato ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer invasion; Cancer associated fibroblasts; Cancer stromal cell interaction; P53; Tetraspanin family

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; PROTEIN P53; TETRASPANIN; TETRASPANIN 12; UNCLASSIFIED DRUG; CXCL6 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TSPAN12 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CONTACT; CELL INVASION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DETERMINATION; DOWN REGULATION; FIBROBLAST; GENE INACTIVATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CHEMOKINE CXCL6; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; SIGNAL TRANSDUCTION; TETRASPANINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924565124     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412062112     Document Type: Article

References (46)

1. Mueller MM, Fusenig NE (2004) Friends or foes: Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839-849.
2. Polyak K, Haviv I, Campbell IG (2009) Co-evolution of tumor cells and their microenvironment. Trends Genet 25(1):30-38.
3. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423-1437.
4. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432(7015):332-337.
5. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
6. Madar S, Goldstein I, Rotter V (2013) 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol Med 19(8):447-453.
7. Olumi AF, et al. (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002-5011.
8. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137(3):413-431.
9. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9(10):724-737.
10. Bar J, Moskovits N, Oren M (2010) Involvement of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol 21(1):47-54.
11. Shimoda M, Mellody KT, Orimo A (2010) Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 21(1):19-25.
12. Kiaris H, et al. (2005) Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65(5):1627-1630.
13. Addadi Y, et al. (2010) p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70(23):9650-9658.
14. Kurose K, et al. (2002) Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32(3):355-357.
15. Patocs A, et al. (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357(25):2543-2551.
16. Fukino K, Shen L, Patocs A, Mutter GL, Eng C (2007) Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 297(19):2103-2111.
17. Hawsawi NM, et al. (2008) Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 68(8):2717-2725.
18. Bar J, et al. (2009) Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 28(6): 933-936.
19. Serru V, Dessen P, Boucheix C, Rubinstein E (2000) Sequence and expression of seven new tetraspans. Biochim Biophys Acta 1478(1):159-163.
20. Zöller M (2009) Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9(1):40-55.
21. Sala-Valdés M, Ailane N, Greco C, Rubinstein E, Boucheix C (2012) Targeting tetraspanins in cancer. Expert Opin Ther Targets 16(10):985-997.
22. Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6(10):801-811.
23. Yáñez-Mó M, Barreiro O, Gordon-Alonso M, Sala-Valdés M, Sánchez-Madrid F (2009) Tetraspanin-enriched microdomains: A functional unit in cell plasma membranes. Trends Cell Biol 19(9):434-446.
24. Nikopoulos K, et al. (2010) Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. Am J Hum Genet 86(2):240-247.
25. Poulter JA, et al. (2010) Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy. Am J Hum Genet 86(2):248-253.
26. Junge HJ, et al. (2009) TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell 139(2):299-311.
27. Xu D, Sharma C, Hemler ME (2009) Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 23(11):3674-3681.
28. Knoblich K, et al. (2014) Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits β-catenin degradation. Cell Mol Life Sci 71(7):1305-1314.
29. Hemler ME (2014) Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 14(1):49-60.
30. Finak G, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518-527.
31. Araki S, et al. (2010) TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120(1):290-302.
32. López-Díaz FJ, et al. (2013) Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response. Mol Cell 50(4):552-564.
33. D'Souza-Schorey C, Clancy JW (2012) Tumor-derived microvesicles: Shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26(12):1287-1299.
34. Kharaziha P, Ceder S, Li Q, Panaretakis T (2012) Tumor cell-derived exosomes: A message in a bottle. Biochim Biophys Acta 1826(1):103-111.
35. Moskovits N, Kalinkovich A, Bar J, Lapidot T, OrenM(2006) p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 66(22):10671-10676.
36. Brentnall TA, et al. (2012) Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS ONE 7(1):e30219.
37. Johnson RA, Ince TA, Scotto KW (2001) Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276(29):27716-27720.
38. Godar S, et al. (2008) Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134(1):62-73.
39. Amson R, et al. (2012) Reciprocal repression between P53 and TCTP. Nat Med 18(1): 91-99.
40. Otsubo C, et al. (2014) TSPAN2 is involved in cell invasion and motility during lung cancer progression. Cell Reports 7(2):527-538.
41. Böhlig L, Rother K (2011) One function-multiple mechanisms: The manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol 2011:464916.
42. Li M, et al. (2012) Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell 46(1): 30-42.
43. Gonda TA, Varro A, Wang TC, Tycko B (2010) Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol 21(1):2-10.
44. Bissell MJ, Hines WC (2011) Why don' t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320-329.
45. Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346-354.
46. Endo Y, et al. (2008) Regulation of clathrin-mediated endocytosis by p53. Genes Cells 13(4):375-386.